Inspire Medical Systems, Inc. $INSP Shares Sold by Lazard Asset Management LLC

Lazard Asset Management LLC trimmed its holdings in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 57.9% in the first quarter, Holdings Channel reports. The institutional investor owned 18,938 shares of the company’s stock after selling 26,043 shares during the period. Lazard Asset Management LLC’s holdings in Inspire Medical Systems were worth $977,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Royal Bank of Canada raised its position in shares of Inspire Medical Systems by 16.0% during the 1st quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock worth $5,220,000 after acquiring an additional 4,528 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in Inspire Medical Systems in the first quarter valued at approximately $524,000. Goldman Sachs Group Inc. boosted its holdings in Inspire Medical Systems by 57.9% in the first quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock valued at $8,190,000 after purchasing an additional 18,857 shares in the last quarter. Marshall Wace LLP increased its stake in Inspire Medical Systems by 3.8% in the second quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock valued at $2,064,000 after purchasing an additional 577 shares during the last quarter. Finally, Jump Financial LLC purchased a new position in Inspire Medical Systems in the second quarter valued at approximately $931,000. 94.91% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Inspire reported better-than-expected second-quarter results and raised its fiscal 2026 outlook. The earnings beat, improved cost control and growing contribution from the Inspire V product mix helped offset weaker U.S. procedure activity. Inspire Medical Q2 Earnings Beat Estimates, ’26 View Raised, Stock Up
• Positive Sentiment: Analyst sentiment improved following the results. Oppenheimer upgraded INSP to “outperform” with an $85 price target, while Mizuho raised its target to $65 and maintained an “outperform” rating. Inspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Results
• Positive Sentiment: Longer-term support comes from the company’s large sleep-apnea market opportunity, improving margins and debt-free balance sheet. Recent commentary also suggests reimbursement headwinds may be beginning to ease. Is INSP a Buy as Margins Improve but Reimbursement Risks Persist?
• Neutral Sentiment: JPMorgan raised its price target to $60 and kept a “neutral” rating, while Robert W. Baird increased its target to $59 and also remained “neutral,” indicating that some analysts view the recent gains as largely reflected in the valuation.
• Negative Sentiment: Revenue declined 7.6% year over year, and reimbursement pressure continues to limit U.S. sleep-apnea procedures. The stock’s roughly 28% one-month rally may also be encouraging profit-taking after the earnings news. INSP’s 28.1% Past-Month Rally Raises a Key Question for Investors

Inspire Medical Systems Stock Down 6.4%

Shares of INSP stock opened at $60.01 on Thursday. The stock’s 50-day moving average price is $46.95 and its 200 day moving average price is $54.71. The stock has a market capitalization of $1.73 billion, a PE ratio of 12.99, a price-to-earnings-growth ratio of 4.82 and a beta of 0.70. Inspire Medical Systems, Inc. has a 52-week low of $38.91 and a 52-week high of $147.03.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The company had revenue of $200.58 million during the quarter, compared to analysts’ expectations of $194.72 million. During the same period last year, the firm earned $0.45 EPS. The firm’s revenue for the quarter was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Analysts expect that Inspire Medical Systems, Inc. will post 1.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on INSP shares. KeyCorp reissued a “sector weight” rating on shares of Inspire Medical Systems in a report on Tuesday. Zacks Research upgraded shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Piper Sandler increased their target price on shares of Inspire Medical Systems from $55.00 to $60.00 and gave the company a “neutral” rating in a research report on Tuesday. Truist Financial reiterated a “hold” rating and set a $62.00 price target (up from $54.00) on shares of Inspire Medical Systems in a research note on Tuesday. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a $60.00 price target on shares of Inspire Medical Systems in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $68.00.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.